Biogen Inc

30. Okt. 2026, 23:46 UTC

Biogen Inc. shares are modestly lower in after-market trading, retracing from an early gain and sitting near the low end of their recent range.

29. Okt. 2026, 23:06 UTC

Biogen Inc. receives an upgrade to Buy from Argus Research with a price target of $280, while Canaccord Genuity raises its target to $272.

28. Okt. 2026, 23:01 UTC

Baird analyst Brian Skorney raises Biogen price target while maintaining an Outperform rating, as shares are modestly lower in after-market trading.

26. Okt. 2026, 20:06 UTC

Biogen Canada announced a draft recommendation for expanded public reimbursement of Spinraza, a treatment for spinal muscular atrophy (SMA).

23. Okt. 2026, 23:31 UTC

Biogen Inc shares are trading higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

22. Okt. 2026, 22:31 UTC

Biogen Inc shares are modestly lower in after-market trading, having retraced from earlier gains, with a cumulative return dipping to nearly 0.6%.

21. Okt. 2026, 23:46 UTC

Biogen Inc is advancing in after-market trading, reaching a high near the upper end of its one-month range, maintaining a solid position above its 20-day moving average.

20. Okt. 2026, 23:06 UTC

RBC Capital identifies Biogen as a top pick, maintaining an Outperform rating with a price target of $256 amid a catalyst-rich period.

19. Okt. 2026, 20:13 UTC

Biogen Inc shares advanced in after-market trading, maintaining a cumulative return since Monday's close and remaining above its 20-day moving average.

16. Okt. 2026, 23:16 UTC

Biogen Inc's shares are modestly higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

15. Okt. 2026, 23:16 UTC

Biogen Inc shares advanced modestly in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month range.

14. Okt. 2026, 19:26 UTC

Shares of Biogen Inc are advancing, influenced by recent U.S. inflation reports, and remain above their 20-day moving average during Wednesday's session.

13. Okt. 2026, 20:08 UTC

Biogen Inc shares are declining, following a slight drop from Monday's close.

12. Okt. 2026, 22:21 UTC

Biogen Inc shares advanced during after-market hours on Monday, continuing a trend of higher movement since the prior close.

9. Okt. 2026, 20:07 UTC

UBS reaffirms Buy rating on Biogen Inc and raises price target to $270 from $240, while CCB International initiates coverage with an Outperform rating.

8. Okt. 2026, 20:07 UTC

RBC Capital lowers Biogen price target to $256 from $260 while maintaining an Outperform rating, reflecting ongoing evaluations of the company's performance and market conditions.

7. Okt. 2026, 23:45 UTC

Biogen Inc. is seeing a modest decline in after-market trading, stabilizing at a level nearly half a percent below Wednesday's close.

6. Okt. 2026, 20:06 UTC

Biogen Inc's shares fell, reflecting a slight decline from Monday's close, despite peaking in the morning and remaining near the upper end of their one-month range.

5. Okt. 2026, 23:25 UTC

Biogen Inc is trading modestly lower in after-market hours, reflecting a decline since Monday's close and stabilizing within its one-month trading range.

2. Okt. 2026, 23:15 UTC

Biogen Inc. has declined during after-market hours, marking its sixth consecutive session of lower closes and reaching a cumulative return low.

1. Okt. 2026, 23:55 UTC

Biogen Inc is trading modestly higher in after-market hours, maintaining a position above its 20-day moving average and near its one-month range.

28. Sept. 2026, 19:15 UTC

Biogen Inc is seeing a modest gain, retracing above its 20-day moving average and near the upper end of its one-month range.

25. Sept. 2026, 19:26 UTC

Biogen Inc is trading slightly higher, remaining above its 20-day moving average and near the upper end of its one-month range.

24. Sept. 2026, 23:05 UTC

Biogen Inc is trading modestly higher in after-market hours, reflecting solid performance above its 20-day moving average and near the upper end of its one-month range.

23. Sept. 2026, 19:36 UTC

Biogen Inc is seeing modest gains as it releases adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI, targeting rare kidney diseases.

22. Sept. 2026, 23:50 UTC

Biogen Inc is trading lower in after-market hours, experiencing fluctuations despite remaining above its 20-day moving average and near the upper end of its one-month range.

21. Sept. 2026, 23:05 UTC

Biogen Inc. is trading slightly higher in after-market hours following approvals for at-home LEQEMBI in Japan and China and new Phase 3 data for EMPAVELI.

18. Sept. 2026, 20:02 UTC

Biogen Inc shares fell sharply, reversing a trend of higher daily closes observed in recent sessions and breaking from upward momentum since Thursday's close.

17. Sept. 2026, 20:07 UTC

Biogen Inc. shares advanced after Japan approved its subcutaneous formulation of LEQEMBI®, enhancing its Alzheimer's treatment portfolio in today's trading.

16. Sept. 2026, 20:21 UTC

Biogen Inc's LEQEMBI® receives approval in Japan for a new administration route, while the stock is modestly lower in after-market trading.